AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20394491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% combined with fluticasone
Number of subjects: 376
Study 20394491 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone
Number of subjects: 376
Study 18759257 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg (group 2)
Number of subjects: 279
Study 18759257 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by infliximab 5 mg/kg (group 1)
Number of subjects: 279
Study 15897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (exercise, massage, taping, and mobilisation)
Number of subjects: 140
Study 15897310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham ultrasound and non-therapeutic gel)
Number of subjects: 140
Study 12689932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord Blood (CB) transplant
Number of subjects: 24
Study 12689932 — intervention group
Group type: COMPARATOR
Intervention: Adult Bone Marrow (BM) transplant
Number of subjects: 24
Study 10584627 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine curettage under general anesthesia
Number of subjects: 55
Study 10584627 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (no curettage)
Number of subjects: 55
Study 8592224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate 6 mg/kg per day
Number of subjects: 1023
Study 8592224 — intervention group
Group type: COMPARATOR
Intervention: Tirilazad mesylate 0.6 mg/kg per day
Number of subjects: 1023
Study 8592224 — intervention group
Group type: COMPARATOR
Intervention: Tirilazad mesylate 2 mg/kg per day
Number of subjects: 1023
Study 8592224 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 1023
Study 1868479 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment alone for reflux grade III or less
Number of subjects: 96
Study 1868479 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus antibiotic treatment for reflux grade IV
Number of subjects: 96
Study 1868479 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimplantation for reflux grade V
Number of subjects: 96
Study 1868479 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment alone for reflux grade IV (control group)
Number of subjects: 96
Study 6202972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg three times a day for 7 days
Number of subjects: 29
Study 6202972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30614823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading, followed by 90 mg twice daily
Number of subjects: 298
Study 29336389 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 29336389 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 27412058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve patients
Number of subjects: 80
Study 27412058 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal trileaflet aortic valve)
Number of subjects: 80
Study 24314872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular Tridimensional Memory Fixation System (ATMFS)
Number of subjects: 50
Study 24314872 — intervention group
Group type: COMPARATOR
Intervention: Conventional screws and buttress plates (Plates group)
Number of subjects: 50
Study 22515969 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (n = 552)
Number of subjects: 1093
Study 22515969 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 541)
Number of subjects: 1093
Study 20494923 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 6676
Study 20494923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6676
Study 17763834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsants
Number of subjects: 0
Study 17763834 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure prophylaxis with antiepileptic drugs
Number of subjects: 0
Study 17763834 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature on prophylactic anticonvulsants
Number of subjects: 0
Study 17414940 — intervention group
Group type: EXPERIMENTAL
Intervention: NT 201 (2, 4, 16, or 32 units)
Number of subjects: 32
Study 17414940 — intervention group
Group type: COMPARATOR
Intervention: Botox (BTXCo)
Number of subjects: 32
Study 15815753 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy with the RESCUE system followed by stent implantation
Number of subjects: 72
Study 15815753 — intervention group
Group type: COMPARATOR
Intervention: PCI with stent implantation alone
Number of subjects: 72
Study 11232739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme
Number of subjects: 1290
Study 11232739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmaceutical care)
Number of subjects: 1290
Study 9288859 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ASA (4 g/day Pentasa)
Number of subjects: 153
Study 9288859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 8321504 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes of black patients
Number of subjects: 271
Study 3471376 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 0.2% neutral NaF rinse
Number of subjects: 501
Study 3471376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride rinse)
Number of subjects: 501
Study 30954486 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment (16 mg/kg)
Number of subjects: 2
Study 30954486 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment
Number of subjects: 2
Study 30954486 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Locke's buffer)
Number of subjects: 2
Study 28174212 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 783
Study 28174212 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 783
Study 25770870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of the Helpful Responses Questionnaire (HRQ)
Number of subjects: 19
Study 25770870 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-choice CM knowledge test
Number of subjects: 19
Study 25770870 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded standardized patient encounter scored for CM skillfulness
Number of subjects: 19
Study 24955290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month multi-component intervention
Number of subjects: 136
Study 21371292 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative continuation of ASA
Number of subjects: 52
Study 21371292 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of ASA (stopping ASA five days prior to surgery and starting on postoperative day 5)
Number of subjects: 52
Study 20168107 — intervention group
Group type: EXPERIMENTAL
Intervention: One biopsy
Number of subjects: 988
Study 20168107 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more biopsies
Number of subjects: 988
Study 20168107 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero biopsies
Number of subjects: 988
Study 16775818 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting procedures
Number of subjects: 108
Study 16775818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quilting)
Number of subjects: 108
Study 15261228 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12
Study 15261228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12
Study 15261228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 12
Study 11583189 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide (HEC)
Number of subjects: 481
Study 9855147 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy
Number of subjects: 34
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related decline in speed of sound (SOS)
Number of subjects: 1405
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related decline in broadband ultrasound attenuation (BUA)
Number of subjects: 1405
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Current corticosteroid use
Number of subjects: 1405
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disability
Number of subjects: 1405
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack-years of smoking
Number of subjects: 1405
Study 7863827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements (SOS and BUA) compared to bone mineral density (BMD)
Number of subjects: 1405
Study 2574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg once daily
Number of subjects: 6
Study 2574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg twice daily
Number of subjects: 6
Study 2574050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30584179 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR combined with 640-slice CT wide-detector volume scan
Number of subjects: 58
Study 30584179 — intervention group
Group type: COMPARATOR
Intervention: ASIR combined with conventional spiral scan
Number of subjects: 58
Study 27464913 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis' flap procedure
Number of subjects: 50
Study 27464913 — intervention group
Group type: COMPARATOR
Intervention: Limberg's flap procedure
Number of subjects: 50
Study 25985442 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the left DLPFC
Number of subjects: 0
Study 25985442 — intervention group
Group type: COMPARATOR
Intervention: Cathodal stimulation of the left DLPFC
Number of subjects: 0
Study 25985442 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the left DLPFC
Number of subjects: 0
Study 23793032 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-based encouragements to walk the stairs for 10 minutes a day
Number of subjects: 160
Study 23793032 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving weekly reminders to continue their usual physical activities
Number of subjects: 160
Study 21782470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 30
Study 21782470 — intervention group
Group type: COMPARATOR
Intervention: Unguided injection
Number of subjects: 30
Study 19533164 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Number of subjects: 30
Study 19533164 — intervention group
Group type: COMPARATOR
Intervention: Lower limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Number of subjects: 30
Study 19533164 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 30
Study 16709552 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-15 mg/d)
Number of subjects: 46
Study 16709552 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1-6 mg/d)
Number of subjects: 46
Study 15329581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg x kg(‐1) x min(‐1))
Number of subjects: 40
Study 15329581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11703440 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (PE)
Number of subjects: 22
Study 11703440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 22
Study 9407756 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg
Number of subjects: 48
Study 9407756 — intervention group
Group type: COMPARATOR
Intervention: Naproxen granular 500 mg
Number of subjects: 48
Study 8505452 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide gel
Number of subjects: 0
Study 8505452 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 3429683 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (twice daily for eight weeks)
Number of subjects: 12
Study 3429683 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (once daily for eight weeks)
Number of subjects: 12
Study 3429683 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated whole-day ambulatory blood pressure monitoring
Number of subjects: 12
Study 30839494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon α2b 1 MU/mL
Number of subjects: 50
Study 30839494 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear eye drop
Number of subjects: 50
Study 27867204 — intervention group
Group type: EXPERIMENTAL
Intervention: 10TT
Number of subjects: 537
Study 27867204 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 537
Study 24762404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification of Interpretations (CBM-I)
Number of subjects: 34
Study 24762404 — intervention group
Group type: COMPARATOR
Intervention: Test-retest control group
Number of subjects: 34
Study 23264335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MM)
Number of subjects: 31
Study 23264335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 31
Study 21622980 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin given intravenously for 48 hours
Number of subjects: 234
Study 21622980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 19085546 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vault technique (group A)
Number of subjects: 53
Study 19085546 — intervention group
Group type: COMPARATOR
Intervention: Open vault technique (group B)
Number of subjects: 53
Study 16880100 — intervention group
Group type: EXPERIMENTAL
Intervention: PB127 (0.175 mg/kg diluted in 5% dextrose)
Number of subjects: 20
Study 16880100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.56 mg/kg)
Number of subjects: 20
Study 16880100 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 20
Study 12628263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 344
Study 12628263 — intervention group
Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study 10848655 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days (OCT)
Number of subjects: 2329
Study 10848655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2329
Study 10848655 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 2329
Study 9385471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclamptic patients
Number of subjects: 2
Study 9385471 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant controls
Number of subjects: 2
Study 8031400 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier on the inspiratory limb of the breathing circuit (39 degrees C, 90% relative humidity)
Number of subjects: 43
Study 8031400 — intervention group
Group type: COMPARATOR
Intervention: No heated humidifier (abdominal operations)
Number of subjects: 43
Study 8031400 — intervention group
Group type: COMPARATOR
Intervention: No heated humidifier (limb operations)
Number of subjects: 43
Study 3230459 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents who audited their own charts for 1985 influenza vaccination ordering
Number of subjects: 3
Study 3230459 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents who audited their own charts for 1985 screening mammography ordering
Number of subjects: 3
Study 3230459 — intervention group
Group type: COMPARATOR
Intervention: Passive receipt of results (control group)
Number of subjects: 3
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) confined to the culprit lesion
Number of subjects: 0
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion only PCI
Number of subjects: 0
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radial access for PCI
Number of subjects: 0
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 0
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0
Study 31082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion only PCI in multivessel disease
Number of subjects: 0
Study 27693921 — intervention group
Group type: EXPERIMENTAL
Intervention: MOV
Number of subjects: 52
Study 27693921 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 52
Study 27693921 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 52
Study 26135803 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 or 1.5 mg three times daily)
Number of subjects: 0
Study 26135803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26135803 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 mg three times daily) in PATENT-2
Number of subjects: 0
Study 23090499 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin)
Number of subjects: 91
Study 23090499 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD-HAM induction (high dose cytarabine, mitoxantrone)
Number of subjects: 91
Study 23090499 — intervention group
Group type: COMPARATOR
Intervention: Non-eligible patients
Number of subjects: 91
Study 23090499 — intervention group
Group type: COMPARATOR
Intervention: Study patients
Number of subjects: 91
Study 21985684 — intervention group
Group type: EXPERIMENTAL
Intervention: ePsychNurse.Net (eLearning course)
Number of subjects: 158
Study 21985684 — intervention group
Group type: COMPARATOR
Intervention: Education as usual (control)
Number of subjects: 158
Study 17961576 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation (52 g of soy protein containing 112 mg of isoflavones) for 8 weeks
Number of subjects: 40
Study 17961576 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40
Study 17961576 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol producers (prior to soy supplementation)
Number of subjects: 40
Study 17961576 — intervention group
Group type: COMPARATOR
Intervention: Non-equol producers (prior to soy supplementation)
Number of subjects: 40
Study 17132972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramiprosate (50, 100, or 150 mg twice daily for 12 weeks)
Number of subjects: 24
Study 14630680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (more intensive in GELA group)
Number of subjects: 44
Study 14630680 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection plus chemotherapy (GELD group)
Number of subjects: 44
Study 14630680 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (GELA group)
Number of subjects: 44
Study 12835883 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 3 g in 15 ml suspension enema
Number of subjects: 134
Study 12835883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 4 g gel enema
Number of subjects: 134
Study 12835883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg foam enema
Number of subjects: 134
Study 10389782 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.5 mg/kg
Number of subjects: 60
Study 10389782 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 8540847 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at 120 mg/kg per day
Number of subjects: 279
Study 8540847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day
Number of subjects: 279
Study 8540847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy: induction with the other drug for 2 weeks followed by maintenance therapy with both drugs (ganciclovir at 5 mg/kg per day and foscarnet at 90 mg/kg per day)
Number of subjects: 279
Study 1902405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy (both t-PA and urokinase)
Number of subjects: 575
Study 1902405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive catheterization strategy
Number of subjects: 575
Study 6201270 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHM plus amphotericin B (AMB)
Number of subjects: 37
Study 6201270 — intervention group
Group type: COMPARATOR
Intervention: ACHM
Number of subjects: 37
Study 6201270 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHM plus AMB
Number of subjects: 37
Study 3094807 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mydriatic retinal photography
Number of subjects: 62
Study 29166666 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Compression Brace (ACB)
Number of subjects: 14
Study 29166666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25444793 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine (5 μg, 15 μg, 50 μg, and 150 μg doses)
Number of subjects: 4
Study 25444793 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine
Number of subjects: 4
Study 23240761 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 66
Study 23240761 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66
Study 23240761 — intervention group
Group type: COMPARATOR
Intervention: Low TFMP group (no intervention specified)
Number of subjects: 66
Study 21663486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 high dose (17.2 billion CFU)
Number of subjects: 100
Study 21663486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 low dose (1.8 billion CFU)
Number of subjects: 100
Study 21663486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 4 degrees C
Number of subjects: 40
Study 17659770 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 24 degrees C
Number of subjects: 40